IL326351A - Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof - Google Patents

Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof

Info

Publication number
IL326351A
IL326351A IL326351A IL32635126A IL326351A IL 326351 A IL326351 A IL 326351A IL 326351 A IL326351 A IL 326351A IL 32635126 A IL32635126 A IL 32635126A IL 326351 A IL326351 A IL 326351A
Authority
IL
Israel
Prior art keywords
antigens
herpes simplex
simplex virus
virus glycoprotein
rna compositions
Prior art date
Application number
IL326351A
Other languages
Hebrew (he)
Original Assignee
Univ Pennsylvania
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, BioNTech SE filed Critical Univ Pennsylvania
Publication of IL326351A publication Critical patent/IL326351A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL326351A 2023-08-03 2024-08-02 Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof IL326351A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363517578P 2023-08-03 2023-08-03
PCT/US2024/040734 WO2025030103A1 (en) 2023-08-03 2024-08-02 Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof

Publications (1)

Publication Number Publication Date
IL326351A true IL326351A (en) 2026-04-01

Family

ID=92538551

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326351A IL326351A (en) 2023-08-03 2024-08-02 Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof

Country Status (4)

Country Link
CN (1) CN121843710A (en)
AU (1) AU2024316992A1 (en)
IL (1) IL326351A (en)
WO (1) WO2025030103A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026015882A1 (en) * 2024-07-12 2026-01-15 BioNTech SE Hsv antigen fragments and related methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4998993A (en) 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
CN1118572A (en) 1993-03-05 1996-03-13 萨依特尔有限公司 HLA-A2.1 combination peptide and its use
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ATE490267T1 (en) 2001-06-05 2010-12-15 Curevac Gmbh STABILIZED MRNA WITH INCREASED G/C CONTENT CODING A VIRAL ANTIGEN
EP3611266B1 (en) 2005-08-23 2022-11-09 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
US20130028925A1 (en) 2006-12-28 2013-01-31 Harvey Friedman Herpes simplex virus combined subunit vaccines and methods of use thereof
CA2816925C (en) 2009-11-04 2023-01-10 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
US20180303925A1 (en) 2015-04-27 2018-10-25 The Trustees Of The University Of Pennsylvania Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN111246854A (en) 2017-08-17 2020-06-05 宾夕法尼亚大学理事会 Modified mRNA vaccine encoding herpes simplex virus glycoprotein and use thereof
US11421002B2 (en) * 2017-08-30 2022-08-23 Km Biologics Co., Ltd. Modified HSV gB protein and HSV vaccine including same

Also Published As

Publication number Publication date
CN121843710A (en) 2026-04-10
WO2025030103A1 (en) 2025-02-06
AU2024316992A1 (en) 2026-03-12

Similar Documents

Publication Publication Date Title
WO2023107999A3 (en) Herpes simplex virus mrna vaccines
EP4242223A3 (en) Modified mrna vaccines encoding herpes simplex virus glycoproteins and uses thereof
IL326351A (en) Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof
WO2008099189A3 (en) Herpes simplex viruses and methods of viral replication
ZA202206789B (en) Varicella-zoster virus vaccine and application thereof
MA37446B1 (en) Multivalent recombinant avian herpes virus and vaccines to immunize avian species
AU2003246373A1 (en) Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions
MX342639B (en) High titer recombinant influenza viruses for vaccines and gene therapy.
IL314324A (en) Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
WO2006083286A3 (en) Genetically engineered swine influenza virus and uses thereof
ZA202305129B (en) Recombinant hvt and uses thereof
PT1053017E (en) VACCINES UNDERSTANDING INTERLEUCIN-12 AND HERPES SIMPLEX VIRUS ANTIGEN
WO2020028719A3 (en) Compositions comprising herpes simplex virus-1 for use in methods of treating and preventing cancer
IL318053A (en) Self-amplifying rna encoding an influenza virus antigen
IL321612A (en) Oncolytic virus and uses thereof
IL326358A (en) Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof
CA3300532A1 (en) Rna compositions encoding herpes simplex virus glycoprotein b antigens and uses thereof
CA3300517A1 (en) Rna compositions encoding herpes simplex virus glycoprotein e and/or glycoprotein i antigens and uses thereof
EP1731599A4 (en) Method of constructing recombinant herpes simplex virus
WO2005012538A3 (en) Accelerated vaccination
ZA202104496B (en) Recombinant herpes simplex virus vector, recombinant virus and pharmaceutical composition thereof
IL317408A (en) Viral peptides and uses thereof
ZA202104183B (en) Recombinant oncolytic herpes simplex virus type ii and its pharmaceutical composition
EP4319778A4 (en) Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen
CA3279662A1 (en) Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein c, glycoprotein d, and glycoprotein e antigens and related methods